Therefore, USP6 is a viable therapeutic target for overcoming resistance in CML treatment because it inhibits GLS1 ubiquitination, which not only improves GLS1 stability but also plays a crucial role in the survival of CML cells under therapeutic stress. Here, GLS is linked to chronic myelogenous leukemia, BCR-ABL1 positive.